Male fertility and sexual healthcare company Posterity Health has secured $13 million in Series A funding.

Georgetown Equity Partners led the round with participation from existing investors Distributed Ventures, WVV and FCA Venture Partners and new investors SteelSky Ventures and Scrub Capital. 

WHAT IT DOES

Posterity Health, launched in 2021, is a digital male fertility clinic providing access to reproductive urologists who diagnose and treat sexual health and male fertility issues. 

The company offers sperm cryopreservation, in-clinic or in-home fertility testing, low testosterone treatments, supplements, vasectomy and vasectomy reversal.  

"I've committed my career to male reproductive health because it remains one of the most underserved and poorly understood areas within healthcare," Pam Pure, CEO and cofounder of Posterity Health, said in a statement. 

"This funding gives us the opportunity to serve more men and their families, and it also demonstrates that the tide is turning and that men are starting to take a more active role in their own health. I'm proud to be part of that change."

MARKET SNAPSHOT

In 2023, Posterity Health announced a partnership with Mark Cuban Cost Plus Drug Company (MCCPDC) to provide males access to medications to treat infertility, sexual dysfunction and low testosterone. 

A year before, the company secured $6 million in seed funding led by Distributed Ventures. 

Other companies in the male fertility space include direct-to-consumer virtual care company Ro, which acquired male fertility and sperm-testing startup Dadi in 2022. 

Legacy is another male fertility startup and Hims & Hers offers treatment options pertaining to male fertility.